RxDoctor Payments Data

Mark Packer, MD

Plastic Surgery within the Head & Neck · Saint Louis, MONPI 1760470686

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $996 of the $1,655 with a category attached, or 60.2%. 19 manufacturers reported payments, led by Med-el Corporation at 41.0% of the total. Reporting peaked in 2019 at $851 and has fallen 74.4% since, to $218 in 2025.

$1,655in general payments, 2019–2025

Across 42 payments — averaging $39.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Med-el Corporation$679
  • Regeneron Healthcare Solutions, Inc.$209
  • Optinose US, Inc.$132
  • Johnson & Johnson$122
  • Acclarent, Inc$100
  • GSK$83
  • plus $330 from 13 others

What the payments were for

  • Travel & lodging$65940%
  • Food & beverage$99660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic surgery within the head & neck providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$122,187
Medicare patients
423
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate11$6,782
Fluocinolone Acetonide Oil59$2,403
Azelastine Hcl96$2,325
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort42$2,102
Tobramycin-DexamethasoneTobramycin/Dexamethasone38$1,787
Pantoprazole Sodium136$1,656
Fluticasone Propionate142$1,493
Ipratropium Bromide23$754
Famotidine23$670
Ofloxacin26$628
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort11$547
Levocetirizine Dihydrochloride28$470
Doxycycline Hyclate33$405
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$366
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid41$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$132$6,78211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few plastic surgery within the head & neck providers in Missourion file to place this against a meaningful peer group, so we don't.

Other plastic surgery within the head & neck in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →